Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rhophilin Rho GTPase binding protein 2 pseudogene 1 (RHPN2P1) is classified as a pseudogene in humans and is not known to produce a functional protein product[3][6]. It is predicted to be involved in the negative regulation of stress fiber assembly but lacks demonstrated biological activity or clear disease associations[3]. As a pseudogene, RHPN2P1 is not considered a therapeutic target, and there are currently no drugs or biomarkers associated with it. Its role, if any, is likely limited to genomic or transcriptional regulation rather than direct protein function. Key points: - RHPN2P1 is a pseudogene, not a canonical gene coding for a functional protein[3][6]. - There is no evidence that it encodes a druggable target or participates in disease mechanisms as a direct effector. - Pseudogenes often have no biological function, but some may have regulatory impacts at the transcript level; this has not been demonstrated for RHPN2P1[3]. - Most databases (GeneCards, NCBI) clarify its pseudogene status and lack of association with established pathways, functions, disease roles, or pharmacology[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rhophilin Rho GTPase binding protein 2 pseudogene 1 (RHPN2P1).